Segui
Alessio Amatu
Alessio Amatu
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Email verificata su ospedaleniguarda.it
Titolo
Citata da
Citata da
Anno
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
9222015
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
7262016
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 …
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
6322017
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal CancerMET Confers Resistance to EGFR-Targeted Antibodies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
6112013
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
A Amatu, A Sartore-Bianchi, S Siena
ESMO open 1 (2), e000023, 2016
4162016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
2592014
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
1992019
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1832015
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
1592018
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
1312016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer …
A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019
1262019
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena
Annals of Oncology 30, viii5-viii15, 2019
1182019
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
1182016
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
1162015
Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal CancerMGMT as a …
A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ...
Clinical cancer research 19 (8), 2265-2272, 2013
1092013
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
1022017
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
952018
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial.
S Siena, A Sartore-Bianchi, S Lonardi, L Trusolino, C Martino, ...
Journal of Clinical Oncology 33 (15_suppl), 3508-3508, 2015
802015
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ...
Cardiovascular and interventional radiology 32 (6), 1187-1192, 2009
772009
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
A Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ...
British journal of cancer 113 (12), 1730-1734, 2015
732015
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20